Quarterly Activities/Appendix 4C Cash Flow Report

• Record invoiced revenues of $211,000 for the quarter, up 41% from the previous quarter
• New European agreements in Poland, Nordic markets, and Central Asia
• Regulatory approvals activated commercial sales in Vietnam, Thailand, and Turkey

Memphasys Ltd has reported significant quarterly growth, with invoiced revenues reaching $211,000, a 41% increase from the previous quarter. The company has expanded its European distribution network with agreements in Poland, Nordic countries, and Central Asia. Regulatory approvals have enabled commercial sales in Vietnam, Thailand, and Turkey, supported by orders and distributor preparation. Repeat orders from Italy, the UK, and MENA have reinforced demand from existing partners and clinics. Dr. Arne Schierau has joined as Director, Commercial Operations Europe, focusing on market development and sales activity. The company also secured a $3.5 million funding agreement with Peters Investments to support commercial capability, manufacturing, inventory, and market expansion. A potential FDA 510(k) pathway for Felix has been identified, with pre-submission engagement planned to clarify US regulatory requirements.

Memphasys Ltd expects to see continued growth in invoiced revenues and commercial traction as they expand into new markets.

Memphasys Ltd plans to convert its expanding network of commercial partners and IVF clinic trials into active clinic adoption, regular Felix use, and repeat sales.